Get notified when MRNA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • European Patent Office Revoked Moderna's Key Patent (worsened) — The revocation of European Patent No. 3 590 949 led to dismissal of several national infringement cases against Pfizer/BioNTech, weakening Moderna's patent enforcement position.
  • Convertible Notes Debt Service Risk (new) — New risk factors disclose that servicing the $3.0 billion convertible notes may require significant cash and that the company may not have sufficient cash flow, potentially forcing asset sales or dilutive financing.
NASDAQ: MRNA Moderna, Inc. 10-Q

Moderna swings to Q3 operating income of $130M on 29% revenue growth; raises $3B in convertible notes

Filed November 6, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 6, 2025 · ~1 min read

Key Changes

  • high

    Moderna swung to Q3 operating income of $130 million from a $260 million loss a year earlier, driven by 29% revenue growth to $1.31 billion and lower R&D spending.

    MD&A: Operating results verify on EDGAR →
  • high

    The European Patent Office revoked Moderna's key mRNA patent, leading to dismissal of several national cases against Pfizer/BioNTech; proceedings in Germany and the UK remain pending.

    Legal proceedings verify on EDGAR →
  • high

    Moderna issued $3.0 billion of 0.00% Convertible Senior Notes due 2032, with net proceeds of approximately $3.0 billion; new risk factors highlight debt service and conversion risks.

    MD&A: Convertible notes verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (OWL 10-Q) is open in full — no account needed.

Partner

Trade MRNA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Nov 9, 2026 · How we verify